Addressing the issue of opioid dependence and tolerance has public health implications for
the treatment of opioid abuse (both heroin as well as pharmaceutical opioids) and for the
treatment of pain. Recent preclinical data suggest a role for Substance P (NK-1) receptors in
modulating both the acute and chronic response to opioids. The objective of this study is to
determine whether pretreatment with aprepitant, a selective neurokinin-1 (NK-1) antagonist
can reduce the direct response to an opioid agonist (oxycodone) on measures related to abuse
liability and reinforcing effects.
Phase:
N/A
Details
Lead Sponsor:
Sharon Walsh University of Kentucky
Collaborators:
Merck Sharp & Dohme Corp. National Institute on Drug Abuse (NIDA)